Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pharmasset starts Phase 2a HCV combination drug trial
The Phase 2a trial is intended to recruit around 84 patients who are suffering from chronic HCV genotypes 1, 2 or 3 who have not been treated previously.
The Phase 2a trial is intended to recruit around 84 patients who are suffering from chronic HCV genotypes 1, 2 or 3 who have not been treated previously.
The data from randomized, double blind, controlled multi-center clinical trials of Atopiclair in adults, children and, infants aged over 6 months, showed relief and control of the symptoms
Under the agreement, CPC expects to manage and oversee the activities of the Eligibility Review Committee, which will be responsible to identify and confirm the eligibility of no-option
The new company’s product portfolio comprises medicines targeting treatment of inflammatory diseases and conditions including atopic dermatitis, dry eye syndrome, interstitial cystitis, and lymphatic disorders, as well as
The study results demonstrated that the addition of Cimzia to current therapy showed rapid and consistent efficacy across the patients taking certolizumab pegol whether they had previously received
The study is a placebo-controlled, double-blinded, single site Phase I trial which involves 24 healthy women randomized in two groups to monitor the safety and immunogenicity of the
The company expects to disclose the results within eight weeks. Heplisav is an experimental adult hepatitis B vaccine which is evaluated in two Phase 3 studies that are
With this agreement, PharmaNet will have to access potential subjects who are suffering from mild, moderate, or severe impaired renal function. PharmaNet Early Stage Development president Riaz Bandali
In 2002, Amylin had entered into an alliance with Lilly for the global development and commercialization of exenatide, a medicine indicated as a first line treatment for type
Genmed focuses on the delivery of low cost generic pharmaceutical drugs directly to distribution channels. Genmed said prior to the approval it was already approved to distribute 20